{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:05:58Z","timestamp":1784815558589,"version":"3.55.0"},"reference-count":48,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571681"],"award-info":[{"award-number":["82571681"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research and Development Plan of Shaanxi Province","award":["2018SF-106"],"award-info":[{"award-number":["2018SF-106"]}]},{"DOI":"10.13039\/501100004303","name":"Shaanxi Normal University","doi-asserted-by":"publisher","award":["2020TS052"],"award-info":[{"award-number":["2020TS052"]}],"id":[{"id":"10.13039\/501100004303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,9,4]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Currently, an epidermal growth factor receptor variant III (EGFRvIII)-specific peptide (PEPvIII) vaccine has not achieved satisfactory outcomes in several clinical trials for glioblastoma. This is probably due to the poor immunogenicity of the PEPvIII peptide vaccine and the harshly immunosuppressive tumor microenvironment. Hence, identifying strategies to enhance tumor-specific T cell immune responses and reverse immune suppression is crucial for achieving the maximum beneficial therapeutic effect.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To enhance the immunogenicity of the PEPvIII vaccine, we have developed a novel oncolytic adenovirus-based vaccine by genetically incorporating the PEPvIII peptide into the adenovirus hexon protein, naming this construct Ad5-D24-PEPvIII. However, the upregulation of programmed cell death-ligand 1 (PD-L1) expression in the tumor microenvironment following oncolytic virus therapy may limit its therapeutic effectiveness. To address this, we first attempted to co-express soluble programmed cell death 1 (sPD-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in the E4 region of Ad5-D24-PEPvIII. Subsequently, we combined the oncolytic adenovirus-based PEPvIII vaccine carrying GM-CSF with a PD-L1 inhibitor. Two immunocompetent mouse glioma models were used to evaluate their antitumor effects in vivo. The immune cell status within the tumor microenvironment was assessed using flow cytometry and immunohistochemistry. CD8<jats:sup>+<\/jats:sup> T cell immune responses were evaluated by ELISA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Local administration of Ad5-D24-PEPvIII, which presents high copies of tumor-specific antigen PEPvIII in the hexon protein, successfully activated PEPvIII-specific T cell responses. Co-expression of sPD-1 and GM-CSF in the E4 region of Ad5-D24-PEPvIII could increase the release of proinflammatory cytokines, activate myeloid cells and promote the maturation of dendritic cells, thereby further enhancing the activation and proliferation of CD8<jats:sup>+<\/jats:sup> T cells targeting tumor antigens. More importantly, when the oncolytic adenovirus-based PEPvIII vaccine carrying GM-CSF was combined with a PD-L1 inhibitor, it could also broaden the tumor antigenic epitopes and significantly inhibit tumor growth in immunocompetent glioma mouse models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our work suggests that the efficient presentation of PEPvIII, achieved by modifying the hexon protein of the oncolytic adenovirus, combined with the adjuvant function of GM-CSF and blockade of the PD-1\/PD-L1 axis, significantly enhances the therapeutic efficacy of the PEPvIII vaccine against glioblastoma. In addition, this combination strategy also provides a promising and personalized treatment for patients with cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-010750","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:30:23Z","timestamp":1758792623000},"page":"e010750","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Novel oncolytic adenovirus-based PEPvIII vaccine displays a super antitumor effect in glioma models"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3253-8298","authenticated-orcid":false,"given":"Yuankun","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Shaanxi Normal University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0652-2958","authenticated-orcid":false,"given":"Lingyue","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Shaanxi Normal University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6885-2164","authenticated-orcid":false,"given":"Xia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Shaanxi Normal University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9449-2039","authenticated-orcid":false,"given":"Yufan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Shaanxi Normal University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4397-9438","authenticated-orcid":false,"given":"Hongjuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Shaanxi Normal University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8159-106X","authenticated-orcid":false,"given":"Ruru","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Shaanxi Normal University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-4907","authenticated-orcid":false,"given":"Weifeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Shaanxi Normal University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6309-4344","authenticated-orcid":false,"given":"Junli","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Shaanxi Normal University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-024X","authenticated-orcid":false,"given":"Peiyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Shaanxi Normal University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7876-2046","authenticated-orcid":false,"given":"Qinwen","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-5759","authenticated-orcid":false,"given":"Haibin","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Shaanxi Normal University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2025092502301010000_13.9.e010750.1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"key":"2025092502301010000_13.9.e010750.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105780"},{"key":"2025092502301010000_13.9.e010750.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2008.12.005"},{"key":"2025092502301010000_13.9.e010750.4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejphar.2017.05.064","article-title":"The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme","volume":"810","author":"Chistiakov","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"2025092502301010000_13.9.e010750.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2008.04.001"},{"key":"2025092502301010000_13.9.e010750.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30517-X"},{"key":"2025092502301010000_13.9.e010750.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100639"},{"key":"2025092502301010000_13.9.e010750.8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.721830"},{"key":"2025092502301010000_13.9.e010750.9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/mp100214b","article-title":"Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach","volume":"8","author":"Matthews","year":"2011","journal-title":"Mol Pharm"},{"key":"2025092502301010000_13.9.e010750.10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98047"},{"key":"2025092502301010000_13.9.e010750.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0019-2"},{"key":"2025092502301010000_13.9.e010750.12","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ymthe.2018.06.001","article-title":"Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy","volume":"26","author":"Santos","year":"2018","journal-title":"Mol Ther"},{"key":"2025092502301010000_13.9.e010750.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15229-5"},{"key":"2025092502301010000_13.9.e010750.14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002758","article-title":"Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment","volume":"9","author":"Yan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025092502301010000_13.9.e010750.15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1638"},{"key":"2025092502301010000_13.9.e010750.16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.omto.2021.01.010","article-title":"Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment","volume":"20","author":"Tan","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"2025092502301010000_13.9.e010750.17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203251"},{"key":"2025092502301010000_13.9.e010750.18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jprot.2018.11.020","article-title":"Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy","volume":"194","author":"Gonz\u00e1lez-Morales","year":"2019","journal-title":"J Proteomics"},{"key":"2025092502301010000_13.9.e010750.19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.canlet.2021.03.027","article-title":"Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24\/endostatin enhances glioma therapy","volume":"509","author":"Zhang","year":"2021","journal-title":"Cancer Lett"},{"key":"2025092502301010000_13.9.e010750.20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/hum.2011.130","article-title":"A fiber chimeric CRAd vector Ad5\/11-D24 double-armed with TRAIL and arresten for enhanced glioblastoma therapy","volume":"23","author":"Li","year":"2012","journal-title":"Hum Gene Ther"},{"key":"2025092502301010000_13.9.e010750.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2011.12.022"},{"key":"2025092502301010000_13.9.e010750.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12896-015-0121-4","article-title":"A novel adenoviral vector carrying an all-in-one Tet-On system with an autoregulatory loop for tight, inducible transgene expression","volume":"15","author":"Chen","year":"2015","journal-title":"BMC Biotechnol"},{"key":"2025092502301010000_13.9.e010750.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2400"},{"key":"2025092502301010000_13.9.e010750.24","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141614","article-title":"Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy","volume":"131","author":"Panagioti","year":"2021","journal-title":"J Clin Invest"},{"key":"2025092502301010000_13.9.e010750.25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0628"},{"key":"2025092502301010000_13.9.e010750.26","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"Chen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025092502301010000_13.9.e010750.27","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010018","article-title":"Myeloid Cells in Glioblastoma Microenvironment","volume":"10","author":"De Leo","year":"2020","journal-title":"Cells"},{"key":"2025092502301010000_13.9.e010750.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3626"},{"key":"2025092502301010000_13.9.e010750.29","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0156"},{"key":"2025092502301010000_13.9.e010750.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2564"},{"key":"2025092502301010000_13.9.e010750.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat Commun"},{"key":"2025092502301010000_13.9.e010750.32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"key":"2025092502301010000_13.9.e010750.33","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jpha.2023.04.012","article-title":"Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C","volume":"13","author":"Zhu","year":"2023","journal-title":"J Pharm Anal"},{"key":"2025092502301010000_13.9.e010750.34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature New Biol"},{"key":"2025092502301010000_13.9.e010750.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23832-3"},{"key":"2025092502301010000_13.9.e010750.36","article-title":"Immunotherapy: Advancing glioblastoma treatment\u2014A narrative review of scientific studies","volume":"7","author":"Tiwari","year":"2024","journal-title":"Cancer Rep"},{"key":"2025092502301010000_13.9.e010750.37","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-020-02495-x","article-title":"Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro","volume":"69","author":"Burke","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2025092502301010000_13.9.e010750.38","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/cgt.2013.54","article-title":"Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines","volume":"20","author":"Miguel","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"2025092502301010000_13.9.e010750.39","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202301789","article-title":"Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy","volume":"10","author":"Ji","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"2025092502301010000_13.9.e010750.40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754"},{"key":"2025092502301010000_13.9.e010750.41","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396"},{"key":"2025092502301010000_13.9.e010750.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18570-x"},{"key":"2025092502301010000_13.9.e010750.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0482"},{"key":"2025092502301010000_13.9.e010750.44","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/mt.2012.252","article-title":"Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response","volume":"21","author":"Shin","year":"2013","journal-title":"Mol Ther"},{"key":"2025092502301010000_13.9.e010750.45","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21795"},{"key":"2025092502301010000_13.9.e010750.46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic Viruses and the Immune System: The Dynamic Duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025092502301010000_13.9.e010750.47","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.115"},{"key":"2025092502301010000_13.9.e010750.48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1376156","article-title":"Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy","volume":"7","author":"Yan","year":"2017","journal-title":"Oncoimmunology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:30:28Z","timestamp":1758792628000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/jitc-2024-010750"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010750","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}